B.Riley Upgrades Bicycle Therapeutics (BCYC) to Buy, "regulatory barriers have now been lifted"
Tweet Send to a Friend
B.Riley analyst Kalpit Patel upgraded Bicycle Therapeutics (NASDAQ: BCYC) from Neutral to Buy with a price target of $33.00.The analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
